Novocure Limited (NVCR) fundamentals score
Novocure is a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Its therapy is delivered through a medical device.
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NASDAQ
Overall: 5.6 out of 10, Mixed fundamentals
- Growth: 5.8/10
- Profitability: 4.1/10
- Financial health: 5.9/10
- Earnings quality: 6.6/10
- Valuation: 6.4/10
Scores are calculated from Novocure Limited’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10